Sarepta Therapeutics buy tamam
Start price
09.01.18
/
50%
€48.59
Target price
04.11.21
€153.34
Performance (%)
57.44%
End price
05.11.21
€76.50
Summary
This prediction ended on 05.11.21 with a price of €76.50. With a performance of 57.44% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sarepta Therapeutics | 6.156% | 6.156% | -2.425% | -83.812% |
| iShares Core DAX® | -1,06 % | 5,01 % | 6,60 % | 64,71 % |
| iShares Nasdaq 100 | -2,39 % | 0,86 % | 25,79 % | 88,24 % |
| iShares Nikkei 225® | -4,36 % | 1,21 % | 41,31 % | 79,31 % |
| iShares S&P 500 | -1,78 % | 1,39 % | 21,04 % | 69,60 % |
Comments by tamam for this prediction
In the thread Sarepta Therapeutics diskutieren
Sarepta continues to be a core buy in biotech
In today´s investor update management guided for fourth quarter revenue of $57.3 million and full year 2018 Exondys 51 revenue in the range of $295 million to $305 million (roughly double that of 2017).
tamam stimmt am 09.01.2018 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading Sarepta Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten